Abstract | OBJECTIVE: METHODS: We searched for articles involving randomized controlled trials (RCTs) that were published before September 1, 2017, in the PubMed, Clinical Trials, Cochrane Library, and EMBASE databases. A meta-analysis was performed to estimate changes in the scales used to assess neuropsychiatric symptoms. The data were analyzed using Cochrane Collaboration's Review Manager 5.3 software. RESULTS: We identified 8 RCTs involving 1675 subjects. Compared with placebo treatment, treatment with the rotigotine transdermal patch significantly improved scores for the emotion/apathy domains of the Non-Motor Symptoms Scale (NMSS), Beck Depression Inventory-II (BDI-II), Apathy Scale (AS), the sleep/ fatigue domains of the NMSS, the 8-item Parkinson's disease Questionnaire (PDQ-8) and the 39-item PDQ (PDQ-39) (emotion/apathy domain of the NMSS: MD = -2.5, 95% CI [-4.11, 0.89]; BDI-II: MD = -1.19, 95% CI [-2.30, 0.08]; AS: MD = -1.56, 95% CI [-2.67, 0.45]; sleep/ fatigue domain of the NMSS: MD = -2.03, 95% CI [-3.08, 0.98]; PDQ-8: MD = -4.93, 95% CI [-6.79, 3.07]; PDQ-39: MD = -3.52, 95% CI [-5.25, 1.79]; PDQ-8 and PDQ-39: SMD = -0.36,95% CI [-0.49,0.23]). The results of the Parkinson's Disease Sleep Scale 2nd version (PDSS-2) were heterogeneous, and those on the Snaith-Hamilton Pleasure Scale (SHAPS) were not statistically significant (P = .61). CONCLUSION: The rotigotine transdermal patch effectively improved neuropsychiatric symptoms and quality of life in patients with PD. Further studies are warranted.
|
Authors | Hao-Tian Wang, Li Wang, Yi He, Gang Yu |
Journal | Journal of the neurological sciences
(J Neurol Sci)
Vol. 393
Pg. 31-38
(10 15 2018)
ISSN: 1878-5883 [Electronic] Netherlands |
PMID | 30099246
(Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Systematic Review)
|
Copyright | Copyright © 2018 Elsevier B.V. All rights reserved. |
Chemical References |
- Dopamine Agonists
- Psychotropic Drugs
- Tetrahydronaphthalenes
- Thiophenes
- rotigotine
|
Topics |
- Dopamine Agonists
(administration & dosage)
- Humans
- Mental Disorders
(drug therapy, etiology)
- Parkinson Disease
(drug therapy, psychology)
- Psychotropic Drugs
(administration & dosage)
- Randomized Controlled Trials as Topic
- Tetrahydronaphthalenes
(administration & dosage)
- Thiophenes
(administration & dosage)
- Transdermal Patch
|